Literature DB >> 8807499

Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions.

I Arany1, S K Tyring.   

Abstract

Successful immune response to viral infection, such as human papillomavirus (HPV) infection, involves presentation of viral antigens to the immune system, recruitment of T cells and macrophages, and activation of a diverse array of cytokines. Interferons (IFN) are known to exert immunomodulatory functions via activating these pathways. However, the presence of HPV can interact with this process. We employed a reverse transcription-polymerase chain reaction (RT-PCR)-based method to study this phenomenon in biopsies of patients responding well or poorly to IFN treatment. We found that responders show a delayed-type hypersensitivity (DTH) reaction after IFN treatment, in which TH1 cells (interleukin-2, IL-2, IFN-gamma) and macrophages/NK cells (CD16) predominate. Antigen presentation capability (e.g., upregulation of MHC molecules, cytokines) is also enhanced after IFN treatment in responders. The lack of upregulation of MHC molecules (HLA-DR, beta 2-microglobulin) and certain cytokines (IL-1 alpha, IL-2, IFN-gamma) in nonresponders may be due to the overexpression of HPV early (E7) gene in contrast to responders, where HPV late (L1) gene expression predominates. We concluded that differential HPV expression in infected cells can be responsible for an inappropriate IFN-mediated immune response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807499     DOI: 10.1089/jir.1996.16.453

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  9 in total

Review 1.  The management of difficult anogenital warts.

Authors:  A McMillan
Journal:  Sex Transm Infect       Date:  1999-06       Impact factor: 3.519

Review 2.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

3.  Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts.

Authors:  I Arany; S K Tyring; M M Brysk; M A Stanley; M A Tomai; R L Miller; M H Smith; D J McDermott; H B Slade
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

4.  An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum.

Authors:  Sang-Hee Seo; Hyun-Woo Chin; Dong-Wook Jeong; Hyun-Woo Sung
Journal:  Ann Dermatol       Date:  2010-05-17       Impact factor: 1.444

5.  Tissue specific HPV expression and downregulation of local immune responses in condylomas from HIV seropositive individuals.

Authors:  I Arany; T Evans; S K Tyring
Journal:  Sex Transm Infect       Date:  1998-10       Impact factor: 3.519

6.  Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.

Authors:  I Bourgault Villada; M Moyal Barracco; S Berville; M L Bafounta; C Longvert; V Prémel; P Villefroy; E Jullian; T Clerici; B Paniel; B Maillère; J Choppin; J G Guillet
Journal:  Clin Exp Immunol       Date:  2009-07-30       Impact factor: 4.330

7.  A variant upstream of HLA-DRB1 and multiple variants in MICA influence susceptibility to cervical cancer in a Swedish population.

Authors:  Dan Chen; Joanna Hammer; David Lindquist; Annika Idahl; Ulf Gyllensten
Journal:  Cancer Med       Date:  2014-01-07       Impact factor: 4.452

8.  New alternative combination therapy for recalcitrant common warts: the efficacy of imiquimod 5% cream and duct tape combination therapy.

Authors:  Sun Yae Kim; Sung Kyu Jung; Sang Geun Lee; Sang Min Yi; Jae Hwan Kim; Il-Hwan Kim
Journal:  Ann Dermatol       Date:  2013-05-10       Impact factor: 1.444

9.  Pooled analysis of genome-wide association studies of cervical intraepithelial neoplasia 3 (CIN3) identifies a new susceptibility locus.

Authors:  Dan Chen; Stefan Enroth; Han Liu; Yang Sun; Huibo Wang; Min Yu; Lian Deng; Shuhua Xu; Ulf Gyllensten
Journal:  Oncotarget       Date:  2016-07-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.